The person in the role of Biology Research Associate will work with our ventures (including Rasio Therapeutics) in the biotechnology and life-sciences that manufacture and develop products such as DNA libraries, 3D cell printing, oral vaccines and diagnostics for aquaculture, tissue engineering scaffolds, encapsulating enzymes to treat rare diseases, and oncology therapeutics.
Rasio Therapeutics' parent company, Early Charm, has a job opening to work with Rasio Therapeutics and other companies in its Drug Design Portfolio: Business Development and Technical Sales for Drug Design Companies
NFCR commits $1 million in financing to Rasio Therapeutics to develop treatments targeting cancers with limited treatment options
November 25, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the launch of a formal partnership with the National Foundation for Cancer Research (NFCR).
Chappell is a 20-year veteran of the biopharma industry with experience running multiple drug development programs from discovery stage through to clinical trials
November 14, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran medtech and pharmaceutical industry executive, as the company’s CEO.